Study of Tremelimumab in Patients With Advanced Solid Tumors

Part of paid clinical trials in San Francisco, California.

Sponsor
AstraZeneca
Study ID
NCT02527434
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 150 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors

Key Dates

Start date
Nov 2, 2015
Status verified
Oct 2023
Primary completion
Feb 17, 2018
Completion
Mar 28, 2023

Study Design

Enrollment
64 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treme mono to be sequenced to MEDI4736 mono or combination
    tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)

Primary Outcome Measure

Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase [ Time Frame: From baseline to 12 months in the tremelimumab monotherapy phase ]

Locations (3)

FacilityCityStateZIPSite coordinators
Research SiteSan FranciscoCalifornia94158-
Research SiteMemphisTennessee38120-
Research SiteHoustonTexas77030-

Find similar trials in San Francisco, CA

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Research Site· San Francisco, CAResearch Site· Memphis, TNResearch Site· Houston, TX

Related Studies